ERCC1 and non-small cell lung carcinoma: In patients with completely resected non-small-cell lung cancer, ERCC1-negative tumours showed greater benefit from cisplatin-based adjuvant chemotherapy compared with ERCC1-positive tumours (Olaussen et al, 2006).